Khartis Therapeutics

Biotech · Private

Precision oncology therapeutics targeting genetically defined cancers

khartistx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
9
0 granted · 9 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1194ELF ZONE, INC.——
1195Tengen Biomedical Co——
1196VICOLINE MEDICAL, LLC——
1197Khartis Therapeutics——
1198TATEVA THERAPEUTICS INC.——
1199AIMMAX THERAPEUTICS INC—$200K
1200DMC BIOTECHNOLOGIES, INC.—$47M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 9
  • Insulin Growth FACTOR-1 Receptor (IGF-1R) Inhibitors And Methods Of Uses Thereofapplication
  • Insulin Growth FACTOR-1 Receptor (IGF-1R) Inhibitors And Methods Of Uses Thereofapplication
  • Insulin Growth FACTOR-1 Receptor (IGF-1R) Inhibitors And Methods Of Uses Thereofapplication
  • Insulin Growth FACTOR-1 Receptor (IGF-1R) Inhibitors And Methods Of Uses Thereofapplication
  • Insulin Growth FACTOR-1 Receptor (IGF-1R) Inhibitors And Methods Of Uses Thereofapplication
  • Insulin Growth FACTOR-1 Receptor (IGF-1R) Inhibitors And Methods Of Uses Thereofapplication
  • Insulin Growth FACTOR-1 Receptor (IGF-1R) Inhibitors And Methods Of Uses Thereofapplication
  • Insulin Growth FACTOR-1 Receptor (IGF-1R) Inhibitors And Methods Of Uses Thereofapplication
  • Insulin Growth FACTOR-1 Receptor (IGF-1R) Inhibitors And Methods Of Uses Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.